Physician profile
Joshua Stone
NPI 1083026710
$18,490.65
in general payments reported to CMS, 2019-2025
32 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2021: $713 · 2022: $658 · 2023: $2,023 · 2024: $3,692 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,550 · Food and Beverage: $7,270 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,163 · Travel and Lodging: $987 · Education: $29.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,550.00 |
| Food and Beverage | $7,269.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,162.50 |
| Travel and Lodging | $987.24 |
| Education | $29.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,911.34 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Abbvie INC. | $1,790.68 | 2021-2025 | Ubrelvy, Qulipta |
| Tg Therapeutics, INC. | $1,310.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,292.26 | 2021-2025 | |
| Biogen, INC. | $830.60 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Emd Serono, INC. | $578.49 | 2023-2025 | Mavenclad |
| Lilly USA, LLC | $565.28 | 2022-2025 | Emgality, Kisunla, Reyvow |
| Celgene Corporation | $413.14 | 2021-2024 | Zeposia |
| Sk Life Science, INC. | $350.00 | 2023-2025 | Xcopri |
| Pfizer INC. | $264.50 | 2023-2025 | |
| Genzyme Corporation | $255.62 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $250.51 | 2024-2025 | Acthar |
| Amgen INC. | $235.66 | 2024-2025 | Uplizna |
| Eisai INC. | $213.22 | 2023-2025 | |
| Lundbeck LLC | $198.54 | 2024-2025 | Rexulti, Vyepti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $159.89 | 2022-2023 | Ponvory |
| Davol INC. | $130.88 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $123.53 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Stryker Corporation | $120.67 | 2019 | |
| Genentech, INC. | $89.52 | 2024 | Ocrevus, Enspryng |
| Csl Behring | $89.08 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $59.63 | 2024 | Ultomiris |
| Livanova USA, INC. | $49.23 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Inspire Medical Systems, INC. | $42.89 | 2024 | Inspire |
| Neurelis, INC. | $30.01 | 2025 | Valtoco |
| Acorda Therapeutics, INC | $24.24 | 2023 | Inbrija |
| Jazz Pharmaceuticals INC. | $23.58 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.10 | 2022 | |
| Ucb, INC. | $21.04 | 2025 | Zilbrysq |
| Biohaven Pharmaceutical Holding Company LTD. | $15.84 | 2022 | |
| Horizon Therapeutics Plc | $15.20 | 2023 | Uplizna |
| Argenx US, INC. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.